GH Research develops mebufotenin-based treatments for depression and other psychiatric and neurological disorders. It last closed at $17.53 on Nov 20, down 5.55% on the day.
AI Auto Pilots
Is GHRS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GHRS.
From GHRS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
GHRS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 10% below its 20 day and 22% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $17.11, and the nearest resistance the Pivot at $17.71.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 7.3%/day
Key levels
$31.4452 week high+79.3%
$24.77100 day average+41.3%
$21.77200 day average+24.2%
$21.3750 day average+21.9%
$19.81Swing high (Oct 21)+13.0%
$19.3520 day average+10.4%
$18.14Pivot R1+3.5%
$17.71Pivot+1.0%
$17.53Last close
$17.11Pivot S1−2.4%
$12.0452 week low−31.3%
Indicators
RSI (14)
35.56
Weak, oversold below 30
Neutral
MACD
-0.82
Above its signal line
Bullish
Stochastic
20.9
Middle of its range
Neutral
ADX (14)
22.3
Weak trend
Williams %R
-89.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-127.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−5.8%
Change over 10 sessions
Bearish
ATR (14)
$1.28
Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityLow, 16.6%/day
Key levels
$31.4452 week high+79.3%
$24.77100 day average+41.3%
$21.77200 day average+24.2%
$21.3750 day average+21.9%
$19.81Swing high (Oct 21)+13.0%
$19.3520 day average+10.4%
$18.14Pivot R1+3.5%
$17.71Pivot+1.0%
$17.53Last close
$17.11Pivot S1−2.4%
$12.0452 week low−31.3%
Indicators
RSI (14)
38.35
Weak, oversold below 30
Neutral
MACD
-0.98
Below its signal line
Bearish
Stochastic
7.5
Near the bottom of its range
Oversold
ADX (14)
32.0
Trending down
Williams %R
-96.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−35.5%
Change over 10 sessions
Bearish
ATR (14)
$2.91
Typical daily range, 16.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for GHRS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow GHRS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for GHRSHow many large options trades hit GHRS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in GHRS in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GHRS is in one of them and how their past GHRS trades turned out.
GH Research is a biopharmaceutical company based in Dublin, Ireland, that is developing treatments for psychiatric and neurological disorders. Its product candidates are based on mebufotenin, studied as an inhaled treatment called GH001 and as an intravenous treatment called GH002. The company's initial focus is treatment resistant depression, a form of major depressive disorder in which patients have not responded adequately to standard therapies. It has not yet received approval to sell any product, and its intended customers are patients with depression and the healthcare providers who treat them.